Meet Cortalix at CPHI Worldwide 2025 in Frankfurt
Cortalix is excited to announce that we will be attending CPHI Worldwide 2025, held on 28–30 October in Frankfurt, Germany. CPHI is one of the largest global gatherings for the pharmaceutical industry, bringing together professionals from across the entire value chain to exchange knowledge, explore partnerships, and discover the latest innovations.
As a company specialized in VHH antibody discovery and engineering, Cortalix will be present to share insights into the unique advantages of nanobody technology. Our proprietary platforms enable rapid selection, optimization, and development of VHH antibodies tailored to diverse applications. These include radiopharmaceuticals for cancer imaging and therapy, CAR-T cell immunotherapy, and novel diagnostic formats such as next-generation ELISAs and point-of-care assays.
At CPHI, we are particularly looking forward to meeting with potential clients, collaborators, and industry experts who share our passion for advancing nanobody-based solutions. By combining our discovery platforms with strong application know-how, Cortalix is able to support partners from early-stage discovery through to preclinical development.
If you would like to learn more about our technology or explore opportunities for collaboration, we encourage you to connect with us in Frankfurt. You can reach out in advance to schedule a meeting, or simply visit us during the event. We look forward to engaging conversations and new partnerships that will help shape the future of biotherapeutics and diagnostics through VHH antibodies.
Let’s meet in Frankfurt!
For more information about Cortalix: www.cortalix.com
Contact
For Cortalix:
Herman Steen, PhD
CEO Cortalix BV
info@cortalix.com